Prolonged Maternal Zika Viremia as a Marker of Adverse Perinatal Outcomes - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Emerging Infectious Diseases Année : 2021

Prolonged Maternal Zika Viremia as a Marker of Adverse Perinatal Outcomes

Résumé

Whether prolonged maternal viremia after Zika virus infection represents a risk factor for maternal-fetal transmission and subsequent adverse outcomes remains unclear. In this prospective cohort study in French Guiana, we enrolled Zika virus-infected pregnant women with a positive PCR result at inclusion and noninfected pregnant women; both groups underwent serologic testing in each trimester and at delivery during January-July 2016. Prolonged viremia was defined as ongoing virus detection >30 days postinfection. Adverse outcomes (fetal loss or neurologic anomalies) were more common in fetuses and neonates from mothers with prolonged viremia (40.0%) compared with those from infected mothers without prolonged viremia (5.3%, adjusted relative risk [aRR] 7.2 [95% CI 0.9-57.6]) or those from noninfected mothers (6.6%, aRR 6.7 [95% CI 3.0-15.1]). Congenital infections were confirmed more often in fetuses and neonates from mothers with prolonged viremia compared with the other 2 groups (60.0% vs. 26.3% vs. 0.0%, aRR 2.3 [95% CI 0.9-5.5]).
Fichier principal
Vignette du fichier
20-0684.pdf (2.1 Mo) Télécharger le fichier

Dates et versions

pasteur-03149660 , version 1 (23-02-2021)

Licence

Paternité

Identifiants

Citer

Léo Pomar, Véronique Lambert, Séverine Matheus, Céline Pomar, Najeh Hcini, et al.. Prolonged Maternal Zika Viremia as a Marker of Adverse Perinatal Outcomes. Emerging Infectious Diseases, 2021, 27 (2), pp.490-498. ⟨10.3201/eid2702.200684⟩. ⟨pasteur-03149660⟩
49 Consultations
59 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More